Immunotherapy plus chemo-radiation for low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with rectal cancer that has not spread to other parts of the body.
- The tumor is located very low in the rectum, close to the anus (within about 5 cm).
- Your cancer cells have a certain protein pattern called pMMR or are MSS/MSI-L (a lab test will confirm this).
- You have not previously received any treatment for this rectal cancer.
- You are generally in good health (able to care for yourself and perform daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests if adding an immunotherapy drug (tislelizumab) to standard chemoradiation and chemotherapy helps patients with ultra-low rectal cancer. It is for patients whose cancer has not spread and can be removed with surgery.
This trial tests a treatment for rectal cancer that combines chemotherapy and radiation over a longer period, along with an immunotherapy drug called camrelizumab. It aims to shrink the tumor and possibly preserve the anus for people with low-lying rectal cancer.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.